<p>New Delhi: Piramal Pharma on Wednesday swung into the black by reporting a consolidated net profit of Rs 10 crore for the third quarter ended December 2023.</p>.<p>The Mumbai-based drug firm had reported a net loss of Rs 90 crore in the October-December period of the last fiscal.</p>.<p>Its revenue from operations rose to Rs 1,959 crore for the third quarter against Rs 1,716 crore in the year-ago period, Piramal Pharma said in a regulatory filing.</p>.<p>"We continue to build on our improved performance in FY24 with 14 per cent year-on-year (YoY) revenue growth in the third quarter, along with a significant improvement in EBITDA margin," Piramal Pharma Chairperson Nandini Piramal said.</p>.<p>The company's contract development and manufacturing business is delivering healthy growth, with robust order inflows, especially for differentiated offerings and innovation-related work, she added.</p>.<p>'We look forward to continuing our momentum in Q4 and ending the financial year on a positive note,' Piramal noted.</p>.<p>Shares of the company ended 3.74 per cent up at Rs 144.20 apiece on BSE.</p>
<p>New Delhi: Piramal Pharma on Wednesday swung into the black by reporting a consolidated net profit of Rs 10 crore for the third quarter ended December 2023.</p>.<p>The Mumbai-based drug firm had reported a net loss of Rs 90 crore in the October-December period of the last fiscal.</p>.<p>Its revenue from operations rose to Rs 1,959 crore for the third quarter against Rs 1,716 crore in the year-ago period, Piramal Pharma said in a regulatory filing.</p>.<p>"We continue to build on our improved performance in FY24 with 14 per cent year-on-year (YoY) revenue growth in the third quarter, along with a significant improvement in EBITDA margin," Piramal Pharma Chairperson Nandini Piramal said.</p>.<p>The company's contract development and manufacturing business is delivering healthy growth, with robust order inflows, especially for differentiated offerings and innovation-related work, she added.</p>.<p>'We look forward to continuing our momentum in Q4 and ending the financial year on a positive note,' Piramal noted.</p>.<p>Shares of the company ended 3.74 per cent up at Rs 144.20 apiece on BSE.</p>